1178 results about "Bowels diseases" patented technology

This specification describes systems and methods for performing endoscopy, obtaining medical images for inflammatory bowel disease (IBD) and scoring severity of IBD in patients. The methods and systems are configured for using machine learning to determine measurements of various characteristics related to IBD. The methods and systems may also obtain and incorporate electronic health data of patients along with endoscopic data to use for scoring purposes.

The invention relates to the field of biomedical materials, and particularly discloses a manganese dioxide nano-enzyme for treating inflammatory bowel disease as well as a preparation method and application of the manganese dioxide nano-enzyme. The preparation method of the manganese dioxide nano-enzyme comprises the following steps: uniformly mixing an organic solution containing manganese nitrate hexahydrate with a montmorillonite aqueous solution to obtain a mixed reaction solution; the pH value of the mixed reaction solution is adjusted to be under the alkaline condition through alkali liquor, a synthetic reaction is carried out, then centrifugation and washing are carried out, the montmorillonite-loaded manganese dioxide nano-enzyme is obtained, and the manganese dioxide nano-enzyme is of a lamellar structure with the length being 20-400 nm. The manganese dioxide nano enzyme has excellent activity similar to superoxide dismutase, catalase and glutathione peroxidase; meanwhile, the compound also has the capability of removing various free radicals such as DPPH and ABTS, can be used for treating the inflammatory bowel disease, and has a wide application prospect.

The application of the animal bifidobacterium subsp. Lactis BX-245 in relieving the inflammatory bowel disease is characterized in that the animal bifidobacterium subsp. Lactis BX-245 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.26973. The invention also discloses an application of the animal bifidobacterium subsp. Lactis BX-245 in relieving the inflammatory bowel disease. The research aims at discussing the relieving effect of the animal bifidobacterium subsp. Lactis BX-245 on IBD mice induced by dextran sodium sulfate (DSS), and 6-week male C57BL / 6J mice which normally eat and drink water are randomly divided into a normal group (NC group), a model group (IBD group), a common yoghourt (FM group), an animal bifidobacterium subsp. Lactis BX-245 bacterial powder group (BX-245 group) and BX-245 yoghourt (BFM group). The relieving effect of the animal bifidobacterium subsp. Lactis BX-245 and the fermented milk of the animal bifidobacterium subsp. Lactis BX-245 on the symptom of the mouse inflammatory bowel disease is evaluated through weight change, immune factors, targeted metabonomics and metagenomics, and data support is provided for application of the animal bifidobacterium subsp. Lactis BX-245 in products.

To meet the need of a novel therapy for preventing or treating pathological dysbiosis of the gut microbiota, in particular for treating or preventing neurodegenerative diseases or bowel diseases. The present invention relates to the use of a composition comprising a plurality of specific molecules for the treatment of a pathological dysbiosis of the gut microbiota. The pathological dysbiosis of the gut microbiota may be characterized by an excess amount of sulfide-producing bacteria and insufficient butyrate-producing bacteria.

The invention discloses a lactobacillus paracasei SX-M1559 strain and application thereof in preparation of drugs for reducing blood sugar and lipid and resisting inflammation, and belongs to the technical field of microorganisms. The invention discloses a lactobacillus paracasei SX-M1559, and the preservation number of the lactobacillus paracasei SX-M1559 is CCTCC (China Center For Type Culture Collection) NO: M 2025030. According to the lactobacillus paracasei SX-M1559 and the application thereof in preparation of the medicine for reducing blood sugar, blood fat and inflammation, the SX-M1559 is separated from fresh feces of long-life old people, teai county, Zhanjiang city, Guangdong province, the glucose content in a zebra fish hyperglycemia model body and the fat content in a zebra fish hyperlipidemia model body can be remarkably reduced, and the effect of reducing blood sugar, blood fat and inflammation is achieved. The invention provides a theoretical reference and a guidance basis for developing a probiotic preparation for preventing or treating hyperlipidemia, diabetes mellitus and inflammatory bowel disease by utilizing the new strain SX-M1559 of the casei paracasei.

The invention relates to bifidobacterium animalis subsp. Lactis C-2 with an effect of improving inflammatory bowel diseases and application of the bifidobacterium animalis subsp. Lactis C-2. The bifidobacterium animalis subsp. Lactis C-2 is classified and named as Bifidobacterium animalis subsp. Lactis, and the preservation number of the bifidobacterium animalis subsp. Lactis C-2 is GDMCC No: 65455. The bacterial strain can inhibit the colonization of harmful bacteria and promote the colonization of beneficial bacteria and optimize the composition of intestinal microorganisms by regulating the intestinal microecology, repairing the intestinal mechanical barrier, improving the intestinal immune response, inhibiting oxidative stress reaction and other action mechanisms, thereby inducing anti-inflammatory response and improving the intestinal barrier function. Therefore, the bifidobacterium animalis subsp. Lactis C-2 strain is suitable for preparing the medicine with the effect of preventing, improving or treating the inflammatory bowel disease.

The invention provides a Villonella enteritidis strain and an application of the Villonella enteritidis strain. The preservation number of the Villonella enteritidis strain is GDMCC No: 65234. The invention also provides a preparation containing the Wehonor enteritidis, a culture method and application of the Wehonor enteritidis as a labeled microorganism or a target spot in preparation of drugs for screening diseases caused by the Wehonor enteritidis. According to the present invention, the virulence gene and the pathogenicity of the Wehonor enteritidis are analyzed, such that the Wehonor enteritidis has the potential pathogenicity for aggravating the inflammatory bowel disease, and the strain provides specificity in the aspects of biological characteristics, pathogenicity and the like compared with the Wehonor micrococcus, such that the cognition of the Wehonor micrococcus in the intestinal tract is new improved, and the Wehonor micrococcus enteritidis can be used for the treatment of the inflammatory bowel disease. Moreover, a new view angle and a new direction are provided for research on the effect of the Wehonor coccus in the intestinal diseases such as IBD (Infectious Bursal Disease).

The invention discloses a strain of Lactobacillus paracasei SX-G1520 and an application of the Lactobacillus paracasei SX-G1520 in preparation of a lipid-lowering, anti-inflammatory and / or antioxidant product, the preservation number of the Lactobacillus paracasei SX-G1520 is CCTCC (China Center for Type Culture Collection) No: M 2025032, and the Lactobacillus paracasei SX-G1520 is preserved in the China Center for Type Culture Collection on January 6, 2025. The Lactobacillus paracasei SX-G1520 strain provided by the invention has lipid-lowering and antioxidant functions, significantly reduces the content of intestinal neutrophils of a zebra fish inflammatory bowel disease model, shows a significant effect on relieving intestinal inflammation, is good in safety, and has good application prospects. And a new technical choice is provided for developing probiotic preparations for regulating fat metabolism, resisting oxidative stress and preventing and treating inflammatory bowel diseases.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The invention relates to the technical field of medicines, and discloses a mannose / trimethyl chitosan modified MXene material (MTC / MXene), a preparation method and application of the mannose / trimethyl chitosan modified MXene material in prevention and treatment of inflammatory bowel diseases. The MTC / MXene material is obtained by preparing mannose-modified trimethyl chitosan and modifying the mannose-modified trimethyl chitosan on a single-layer MXene nanosheet, compared with a pure MXene material, MTC modification endows MXene with hydrophilicity, rich reaction sites are provided for drug loading, higher oxidation resistance is achieved, meanwhile, through surface functional groups and interlayer gaps of the MXene material, the MXene / MTC / MXene material can be used for preparing the drug, and the drug loading efficiency is improved. Different types of drug molecules are loaded and are used for realizing targeted delivery and controlled release of drugs.

The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.

The invention discloses an inulin gel compound loaded with Prussian blue nano-enzyme and nattokinase and application of the inulin gel compound in treatment of inflammatory bowel disease, the compound is formed by blending the Prussian blue nano-enzyme, the nattokinase and inulin, the Prussian blue nano-enzyme with multiple antioxidant enzyme activities is used for removing a large amount of active oxygen in cells, and the nattokinase is used for treating inflammatory bowel disease. The level of inflammatory factors is reduced, oxidative stress is relieved, and intestinal inflammation is treated; the nattokinase not only can inhibit the formation of intestinal microthrombus and effectively dissolve thrombus through the excellent thrombolysis capability of the nattokinase, but also can synergistically and effectively treat inflammatory bowel diseases through the intestinal microbiota regulation capability of the nattokinase; in addition, the inulin, the Prussian blue nano-enzyme and the nattokinase jointly realize the regulation of intestinal microbiota of the patient with the inflammatory bowel disease, so that the anxiety and depression symptoms related to the inflammatory bowel disease are effectively relieved through microbiota-intestine-brain axis. In general, the invention provides a creative example for treating the inflammatory bowel disease and related intestinal internal and external complications thereof.

The present invention discloses a Lactobacillus plantarum and its application in the preparation of functional preparations for preventing and treating inflammatory bowel disease, as well as antioxidant, anti-inflammatory and antibacterial functions. It has excellent ability to scavenge reactive oxygen species, as well as good probiotic characteristics such as acid tolerance, bile salt tolerance, hydrophobicity, self-aggregation ability and inhibition of common human pathogenic bacteria. At the same time, it can improve intestinal inflammation, has a preventive and therapeutic effect on inflammatory bowel disease, and has high biological safety. It can be used as a probiotic preparation to relieve inflammatory bowel disease, improve intestinal mucosal damage and colon inflammation, providing a new strategy for the prevention and treatment of inflammatory bowel disease and having potential clinical application prospects.

The present invention relates to inflammatory bowel disease model production using patient-derived intestinal organoids, and use thereof, wherein the inflammatory bowel disease model produced by an optimized production method for inflammatory bowel disease model production can be used as a patient-customized bowel disease model by constructing an evaluation method for inflammatory bowel disease drugs.

The invention discloses an attenuated artificial bear gall powder nano preparation, the physical structure of which is a core-shell structure, the core is zinc oxide nanoparticles, the shell is mesoporous SiO2, and artificial bear gall powder is attached to the outer surface of the shell, through the design of the core-shell structure, the dissolution of zinc ions can be reduced while efficient loading and pH response release of the artificial bear gall powder can be realized, and the toxicity of the artificial bear gall powder can be reduced. The toxicity of the preparation is reduced; the invention further discloses a preparation method which has the characteristics of simple steps, low cost and suitability for industrial production. The invention further discloses a novel application range, namely, the compound has a wide clinical application prospect in the fields of inflammatory bowel diseases and the like needing targeted anti-inflammatory treatment.

The invention discloses a mucosal epithelial cell targeted oral ROS response type nano-enzyme as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The oral ROS response type nano-enzyme comprises Ce-CDs carbon dots and a betaine polymer, and the betaine polymer is coated on the surfaces of the Ce-CDs carbon dots to form nano-particles; the Ce-CCDs carbon dots are prepared by taking a metal cerium source and chlorogenic acid as raw materials through a pyrolysis method. Through structural innovation and function integration, the prepared nano-enzyme shows outstanding advantages in the aspects of catalytic activity, targeted delivery, collaborative treatment, industrial application and the like, a new technical scheme is provided for efficient and safe treatment of inflammatory bowel diseases, and the nano-enzyme has remarkable technical innovation and clinical application value.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and / or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.

The invention discloses an application of probiotics Blauria winteriae in the preparation of a medicine or food for improving or treating the inflammatory bowel disease of children, and relates to the field of medicines or foods for improving or treating the inflammatory bowel disease of children. According to the invention, the probiotic Blauria wexlerae is used as an effective component to be prepared into medically and food acceptable dosage forms, so that the children inflammatory bowel disease can be obviously improved or treated, and the application value of the probiotic is improved.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.

Provided are methods, systems, and kits for selecting a patient for treatment with a therapeutic agent based on a presence of a genotype associated with a positive therapeutic response to the therapeutic agent. The therapeutic agent, in some embodiments, is an inhibitor of TL1A activity or expression, such as for example, an anti-TL1A antibody.

The present disclosure provides a compound of formula H having excellent PDE4B inhibitory activity, and a pharmaceutical composition thereof and a use thereof. The compound provided by the present disclosure can be used for effectively treating PDE4-related diseases and disorders, including but not limited to inflammatory respiratory diseases, inflammatory bowel diseases, inflammatory joint diseases, inflammatory skin diseases, inflammatory eye diseases, and diseases or cancers of the peripheral or central nervous system.

This invention discloses a system for predicting the efficacy of inflammatory bowel disease based on multimodal data, relating to the field of medical information processing. The system includes: a multimodal data acquisition module for receiving multimodal data; a text feature extraction module for determining text feature vectors using a text feature extraction model; an endoscopic intestinal mucosal feature recognition module for determining intestinal mucosal features using an endoscopic intestinal mucosal feature recognition model; an image feature recognition module for determining imaging features using an image feature recognition model; a pathological feature extraction module for determining pathological features using a pathological recognition model; and an efficacy prediction module for predicting the efficacy of biologics based on multimodal data features using a Transformer model and fully connected layers. Compared to existing technologies, this invention achieves efficacy prediction of biologics based on the fusion of clinical, pathological, endoscopic, and imaging multimodal features, improving the accuracy and clinical rationality of diagnostic and treatment decisions.

The invention discloses a follow-up visit management system for an inflammatory bowel disease patient, and relates to the technical field of medical management. Comprising a patient management module which is in dynamic butt joint with a hospital information system, synchronizes patient data and endoscopic examination results in real time through an HL7 protocol, and establishes an electronic file containing an inflammatory bowel disease specificity tag; the diagnosis and treatment result module is used for storing structured data with temporal markers, including medication time sequences recorded by three groups of timestamps, administration routes and drug categories, auxiliary examination results accompanied with digestive tract pathological section images and hidden space feature vectors extracted from the images through a convolutional neural network; and the diet module is used for carrying out multi-level classification on diet photos uploaded by the patient through an image recognition unit based on MobileNetV3, and outputting food types and intake estimated values. According to the invention, by integrating the multi-dimensional data of the patient, the disease development trend is predicted, and personalized follow-up visit management is provided.

The invention relates to the technical field of microorganisms, in particular to lactobacillus rhamnosus capable of preventing or treating inflammatory bowel diseases and promoting digestion and application of the lactobacillus rhamnosus, and belongs to the technical field of biological medicine. The invention provides a strain of lactobacillus rhamnosus R7970, wherein the preservation number of the lactobacillus rhamnosus R7970 is CGMCC (China General Microbiological Culture Collection Center) 22244, and the preservation number of the lactobacillus rhamnosus R7970 is CGMCC 22244. The lactobacillus rhamnosus R7970 can be used for effectively preventing inflammatory enteritis (IBD) and has a prevention effect on intestinal inflammation, and meanwhile, the lactobacillus rhamnosus R7970 can be used for improving the nutrition digestion and absorption functions of intestinal tracts. Therefore, the lactobacillus rhamnosus R7970 can be applied to prevention of IBD, can be used for preparing probiotic preparations, common foods, health foods and biological pharmacy for improving intestinal health, is convenient for industrial production, and has great popularization value.

Compositions and methods for detecting gastrointestinal diseases are provided. The present invention relates to compositions and methods for detecting and treating gastrointestinal diseases. The present invention relates to the use of an agent for determining intestinal alkaline phosphatase (iAP) activity and the amount of iAP in a child for the preparation of a kit for use in a method for determining the prognosis of inflammatory bowel disease (IBD) in said child.

Provided herein are methods of using reversible monoacylglycerol lipase (MAGL) inhibitors for the treatment and / or management of inflammatory conditions such as inflammatory pain, inflammatory bowel disease (IBD), Crohn's disease (CD) or ulcerative colitis (UC).

The invention features new a method for treating inflammatory bowel disease, including Crohn's Disease (CD) or ulcerative colitis in a human patient, comprising administering to a patient a combination therapy comprising an anti-α4β7 antibody, a TNFα antagonist, and an immunomodulator.

The invention discloses a bacterial cluster motion single image detection method and system based on deep learning, and the method and system are used for quickly and automatically distinguishing the states of cluster motion, swimming and the like of bacteria. According to the method, high-precision classification is realized by acquiring a long-exposure single blurred image of bacteria in a circular limited space and extracting spatial-temporal characteristics by using a dense connected neural network (DenseNet) with an attention module. The kit is suitable for a high-throughput environment, can be integrated into portable equipment, and is used for early diagnosis and treatment evaluation of diseases such as urinary system infection (UTI) and inflammatory bowel disease (IBD).